Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents

被引:49
作者
Coley, Helen M. [1 ]
Shotton, Christine F. [1 ]
Ajose-Adeogun, Abi [1 ]
Modjtahedi, Helmout [1 ]
Thomas, Hilary [1 ]
机构
[1] Univ Surrey, Div Oncol, Postgrad Med Sch, Guildford GU2 7WG, Surrey, England
关键词
receptor tyrosine kinase inhibition; ovarian cancer; EGFR expressing; drug resistance;
D O I
10.1016/j.bcp.2006.07.022
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study has focused on the use of RTK inhibitors in the treatment of ovarian cancer. We have used the human ovarian cancer cell line PEO1 alongside two in-house derived drug resistant variants: PEO1CarboR (8-fold acquired resistance to carboplatin and cisplatin) and the Pgp expressing PEO1TaxR (15-fold acquired resistance to paclitaxel). These variant cell lines were shown to have a higher expression of EGFR 1.6- and 2.0-fold increase, respectively, compared with the parental cell line. We have shown that the RTK inhibitor GW282974A (an analogue of GW2016; lapatinib) is effective in chemosensitisation of drug resistant EGFR over-expressing cells giving rise to a synergistic effect when used in combination with either cisplatin or paclitaxel in chemosensitivity assays. These effects were also seen at the level of apoptosis using the Annexin V assay and expression levels of the IAP Survivin. A reduction in the downstream signalling effector phosphorylated ERK was seen in both resistant cell lines when GW282974A was used in combination with either cisplatin or paclitaxel. This reduction was not so apparent in cells treated with the single agent GW282974A or cytotoxic agent. Interestingly, we did not show evidence for an enhanced sensitivity to the RTK inhibitor in our EGFR expressing resistant lines versus parental PEO1 cells. However, the paclitaxel resistant cell line appeared more sensitive to the chemosensitising effects of GW282974A, in line with its increased EGFR expression. Our data suggest that RTK inhibition is effective in circumvention of tumour cell drug resistance that occurs in conjunction with EGFR overexpression. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:941 / 948
页数:8
相关论文
共 21 条
[1]   Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues [J].
Bast, RC ;
Pusztai, L ;
Kerns, BJ ;
Macdonald, JA ;
Jordan, P ;
Daly, L ;
Boyer, CM ;
Mendelsohn, J ;
Berchuck, A .
HYBRIDOMA, 1998, 17 (04) :313-321
[2]  
Bible KC, 1997, CANCER RES, V57, P3375
[3]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[4]   Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines [J].
Dai, Q ;
Ling, YH ;
Lia, M ;
Zou, YY ;
Kroog, G ;
Iwata, KK ;
Perez-Soler, R .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1572-1578
[5]   Cancer therapy - Antibodies stage a comeback in cancer treatment [J].
Dickman, S .
SCIENCE, 1998, 280 (5367) :1196-1197
[6]  
Erlichman C, 2001, CANCER RES, V61, P739
[7]   Signal transduction blockade and cancer: combination therapy or multi-targeted inhibitors? [J].
Kerr, DJ ;
La Thangue, NB .
ANNALS OF ONCOLOGY, 2004, 15 (12) :1727-1729
[8]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[9]   Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer [J].
Macleod, K ;
Mullen, P ;
Sewell, J ;
Rabiasz, G ;
Lawrie, S ;
Miller, E ;
Smyth, JF ;
Langdon, SP .
CANCER RESEARCH, 2005, 65 (15) :6789-6800
[10]  
Modjtahedi H, 1998, INT J CANCER, V75, P310, DOI 10.1002/(SICI)1097-0215(19980119)75:2<310::AID-IJC22>3.0.CO